Life Sciences

10 May 2018  |  North America  |  Market Research

Global Tissue Diagnostics Market, Forecast to 2022

Liquid Biopsy for Therapy Monitoring and Reimbursement Cuts Impede Long-term Prospects of Tissue Diagnostics Market

Infographics

×

Key Issues Addressed

Tissue diagnostic techniques are used to recognize specific antigens in preserved tissues. The process includes slicing thin tissue samples that are treated with a hematoxylin and eosin (H&E) stain, and then are formalin-fixed paraffin-embedded (FFPE) to diagnose tumors and other histopathology specimens. This has traditionally required skilled pat...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

Readers of one of Frost & Sullivan’s media partners were invited to participate in an online survey in July 2017 that centered around the state of their laboratories in 2017 and their expectations for 2018. Frost & Sullivan has conducted similar studies among the same targeted respondents since 2012. Where applicable, the study presents year-over...

06 Feb 2018  |  Global  |  Mega Trends

Growth Opportunities in Clinical Trial Data Management and eClinical Solutions Market, Forecast to 2020

Digitization Presents Opportunities for Unified Cloud-based Platform Solutions to Optimize Clinical Trial Workflows

Infographics

×

Key Issues Addressed

The global clinical trial IT market is expected to grow from $2.63 billion in 2016 to $4.29 billion in 2020 at a compound annual growth rate (CAGR) of more than 13.0%. North America will continue to hold the largest market share (by revenue) in 2017, followed by Europe. Increasing clinical trial activities in the emerging Asia-Pacific markets and r...

10 Jan 2018  |  Asia Pacific  |  Mega Trends

APAC Biosimilar Market, Forecast 2025

Patent Expiries, Defined Regulatory Pathways, and Escalating Healthcare Costs to Boost Growth

Infographics

×

Key Issues Addressed Key Benefits

Biosimilars is a massive opportunity; regardless of a slow start, the market will eventually be a huge business. As per Frost & Sullivan’s estimate, biologic drugs worth $70–$80 billion will lose exclusivity in the next 5 years globally and APAC’s contribution would be more than 20%. Countries in the region, such as India, China, and South Ko...

This study provides a roadmap for understanding health information exchange. We provide an in-depth overview of the technical aspects of health information exchange (HIE), review major government initiatives driving health information exchange efforts across the U.S.,  define and describe the major market segments and subsegments, and look at rece...

The key objective of this research service  is to study the European Alzheimers disease medication market based on the three major classes of drugs namely acetylcholinesterase inhibitors, NMDA receptor antagonists and new mechanism/ disease modifying drugs and identify the key current and future trends shaping these market segments.  It also aims...

This study provides a comprehensive analysis of the contract research and manufacturing services (CRAMS) segment in India by focusing on drug discovery to pre-clinical toxicology, Active Pharmaceutical Ingredient (API), Formulations and Injectables. The study is based on detailed primary research, and includes an evaluation of the market size as ...

This market insight provides an overview of Mölnlycke Health Care. The Mölnlycke company was established in 1849 by G.F. Henning as primarily a textile manufacturer. In 1997, Mölnlycke Health Care came in to existence when Nordic Capital acquired the medical devices segment of SCA. The company is currently owned by Investor AB and has seen stea...